Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 0904-7488

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 0904-7488). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mg Carton Label (D962f5af 7642 4c6e B7be 3e089fe48873 00)

Venlafaxine Hydrochloride Extended-Release 150 mg capsules USP in unit dose packaging. The label shows the product name, strength, dosage form as extended-release capsules, and packaging details (100 capsules, 10 strips of 10). Labeler is Major Pharmaceuticals. The label includes storage instructions, dispensing notes, and mentions Rx only status.*

FDA Label Image

75mg Carton Label (D962f5af 7642 4c6e B7be 3e089fe48873 01)

The image shows a unit dose label for Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg strength. The label is from Major Pharmaceuticals and indicates a package containing 100 capsules (10 x 10). It includes storage instructions, a note that the package is not child-resistant and is intended for institutional use, and mentions the drug is made in India and distributed by Major Pharmaceuticals in Indianapolis, IN.*

FDA Label Image

37.5mg Carton Label (D962f5af 7642 4c6e B7be 3e089fe48873 02)

Packaging label for Venlafaxine Hydrochloride Extended-Release Capsules USP, 37.5 mg, unit dose. The label indicates 100 capsules (10 x 10) by Major Pharmaceuticals. It includes dosage strength prominently, pharmacist instructions to dispense with medication guide, storage conditions, and manufacturer information.*

FDA Label Image

Figure (Venlafaxine Fig1)

A scatter plot chart displaying the fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) for venlafaxine and its O-desmethylvenlafaxine (ODV) metabolite across various special populations. These populations include hepatic impairment (cirrhosis, mild, moderate), renal impairment (mild/moderate, hemodialysis), CYP2D6 polymorphism, age over 60 years, and gender differences, showing changes relative to reference values.*

FDA Label Image

Figure (Venlafaxine Fig2)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals of venlafaxine and its metabolite ODV when co-administered with various interacting drugs including ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium. The horizontal axis shows change relative to the reference value for Cmax and AUC parameters.*

FDA Label Image

Figure (Venlafaxine Fig3)

A scatter plot chart showing the fold change and 90% confidence intervals of various analytes related to interacting drugs including ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium. The x-axis represents change relative to a reference value, highlighting pharmacokinetic changes (Cmax and AUC) for each analyte.*

FDA Label Image

Chemical Structure (Venlafaxine Str)

Chemical structure of Venlafaxine Hydrochloride showing the molecular arrangement including a methoxy-substituted phenyl ring, cyclohexanol, and dimethylamino groups with the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.